Abstract
The exportin CRM1 binds nuclear export signals (NESs), and mediates active transport of NES-bearing proteins from the nucleus to the cytoplasm. Structural and biochemical analyses have uncovered the molecular mechanisms underlying CRM1/NES interaction. CRM1 binds NESs through a hydrophobic cleft, whose open or closed conformation facilitates NES binding and release. Several cofactors allosterically modulate the conformation of the NES-binding cleft through intramolecular interactions involving an acidic loop and a C-terminal helix in CRM1. This current model of CRM1-mediated nuclear export has not yet been evaluated in a cellular setting. Here, we describe SRV100, a cellular reporter to interrogate CRM1 nuclear export activity. Using this novel tool, we provide evidence further validating the model of NES binding and release by CRM1. Furthermore, using both SRV100-based cellular assays and in vitro biochemical analyses, we investigate the functional consequences of a recurrent cancer-related mutation, which targets a residue near CRM1 NES-binding cleft. Our data indicate that this mutation does not necessarily abrogate the nuclear export activity of CRM1, but may increase its affinity for NES sequences bearing a more negatively charged C-terminal end.
Similar content being viewed by others
Abbreviations
- AML:
-
Acute myeloid leukemia
- CLL:
-
Chronic lymphocytic leukemia
- CTE motif:
-
C-terminal export motif
- LR-NES:
-
Leucine rich NES
- NES:
-
Nuclear export signal
- NLS:
-
Nuclear localization signal
- NPC:
-
Nuclear pore complex
- K D :
-
Equilibrium dissociation constant
References
Yoneda Y (2000) Nucleocytoplasmic protein traffic and its significance to cell function. Genes Cells 5:777–787
Pemberton LF, Paschal BM (2005) Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic 6:187–198
Dong X, Biswas A, Süel KE et al (2009) Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458:1136–1141. doi:10.1038/nature07975
Monecke T, Güttler T, Neumann P et al (2009) Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 324:1087–1091. doi:10.1126/science.1173388
Dong X, Biswas A, Chook YM (2009) Structural basis for assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 16:558–560. doi:10.1038/nsmb.1586
Fung HY, Fu SC, Brautigam CA, Chook YM (2015) Structural determinants of nuclear export signal orientation in binding to exportin CRM1. Elife 4:e10034
Fung HY, Chook YM (2014) Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27:52–61. doi:10.1016/j.semcancer.2014.03.002
Matsuura Y (2016) Mechanistic Insights from Structural Analyses of Ran-GTPase-Driven Nuclear Export of Proteins and RNAs. J Mol Biol 428:2025–2039. doi:10.1016/j.jmb.2015.09.025
Dickmanns A, Monecke T, Ficner R (2015) Structural basis of targeting the exportin CRM1 in cancer. Cells 4:538–568
Saito N, Matsuura Y (2013) A 2.1-Å-resolution crystal structure of unliganded CRM1 reveals the mechanism of autoinhibition. J Mol Biol 425:350–364. doi:10.1016/j.jmb.2012.11.014
Koyama M, Matsuura Y (2010) An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J 29:2002–2013. doi:10.1038/emboj.2010.89
Fox AM, Ciziene D, McLaughlin SH et al (2011) Electrostatic interactions involving the extreme C terminus of nuclear export factor CRM1 modulate its affinity for cargo. J Biol Chem 286:29325–29335. doi:10.1074/jbc.M111.245092
Noske A, Weichert W, Niesporek S et al (2008) Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112:1733–1743. doi:10.1002/cncr.23354
Shen A, Wang Y, Zhao Y et al (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65:153–159. doi:10.1227/01.NEU.0000348550.47441.4B
Huang WY, Yue L, Qiu WS et al (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32:E315
Yao Y, Dong Y, Lin F et al (2009) The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 21:229–235
Zhou F, Qiu W, Yao R et al (2013) CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol 30:726. doi:10.1007/s12032-013-0726-1
Lin DC, Hao JJ, Nagata Y et al (2014) Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 46:467–473. doi:10.1038/ng.2935
Conforti F, Wang Y, Rodriguez JA et al (2015) Molecular pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling. Clin Cancer Res 21:4508–4513. doi:10.1158/1078-0432.CCR-15-0408
Azmi AS (2014) The evolving role of nuclear transporters in cancer. Semin Cancer Biol 27:1–2. doi:10.1016/j.semcancer.2014.04.011
Kudo N, Wolff B, Sekimoto T et al (1998) Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 242:540–547
Sun Q, Carrasco YP, Hu Y et al (2013) Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA 110:1303–1308
Lapalombella R, Sun Q, Williams K et al (2012) Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120:4621–4634. doi:10.1182/blood-2012-05-429506
Ranganathan P, Yu X, Na C et al (2012) Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120:1765–1773. doi:10.1182/blood-2012-04-423160
Pathria G, Wagner C, Wagner SN (2012) Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol 132:2780–2790. doi:10.1038/jid.2012.233
Kojima K, Kornblau SM, Ruvolo V et al (2013) Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121:4166–4174. doi:10.1182/blood-2012-08-447581
Etchin J, Sanda T, Mansour MR et al (2013) KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 161:117–127. doi:10.1111/bjh.12231
Inoue H, Kauffman M, Shacham S et al (2013) CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 189:2317–2326. doi:10.1016/j.juro.2012.10.018
Kalid O, Toledo Warshaviak D, Shechter S et al (2012) Consensus induced fit docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J Comput Aided Mol Des 26:1217–1228
Güttler T, Madl T, Neumann P et al (2010) NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1. Nat Struct Mol Biol 17:1367–1376. doi:10.1038/nsmb.1931
Terry LJ, Shows EB, Wente SR (2007) Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science 318:1412–1416
Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105. doi:10.1038/nature10113
Rodríguez D, Bretones G, Arango JR et al (2015) Molecular pathogenesis of CLL and its evolution. Int J Hematol 101:219–228
Lawrence MS, Stojanov P, Mermel CH et al (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495–501
Winkelmann N, Rose-Zerilli M, Forster J et al (2015) Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Haematologica 100:e237–e239
Amin N, Seymour EK, Saiya-Cork K et al (2016) A quantitative analysis of Subclonal and clonal gene mutations pre- and post-therapy in chronic lymphocytic leukemia. Clin Cancer Res. doi:10.1158/1078-0432.CCR-15-3103
Rodríguez JA, Henderson BR (2000) Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 275:38589–38596
Arregi I, Falces J, Olazabal-Herrero A et al (2015) Leukemia-associated mutations in nucleophosmin alter recognition by CRM1: molecular basis of aberrant transport. PLoS One 10:e0130610. doi:10.1371/journal.pone.0130610
Huijts CM, Schneiders FL, Garcia-Vallejo JJ et al (2015) mTOR inhibition per se induces nuclear localization of FOXP3 and conversion of invariant NKT (iNKT) cells into immunosuppressive regulatory iNKT cells. J Immunol 195:2038–2045. doi:10.4049/jimmunol.1402710
Rodríguez JA, Span SW, Ferreira CG et al (2002) CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 275:44–53
Stauber RH, Rabenhorst U, Rekik A et al (2006) Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic 7:1461–1472
Engelsma D, Rodriguez JA, Fish A et al (2007) Homodimerization antagonizes nuclear export of survivin. Traffic 8:1495–1502
Rodriguez JA, Lens SM, Span SW et al (2006) Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. Oncogene 25:4867–4879
Knauer SK, Moodt S, Berg T et al (2005) Translocation biosensors to study signal-specific nucleo-cytoplasmic transport, protease activity and protein-protein interactions. Traffic 6:594–606
Fetz V, Knauer SK, Bier C et al (2009) Translocation biosensors—cellular system integrators to dissect CRM1-dependent nuclear export by chemicogenomics. Sensors (Basel) 9:5423–5445
Dian C, Bernaudat F, Langer K et al (2013) Structure of a truncation mutant of the nuclear export factor CRM1 provides insights into the auto-inhibitory role of its C-terminal helix. Structure 21:1338–1349. doi:10.1016/j.str.2013.06.003
Monecke T, Dickmanns A, Ficner R (2014) Allosteric control of the exportin CRM1 unraveled by crystal structure analysis. FEBS J 281:4179–4194. doi:10.1111/febs.12842
Engelsma D, Bernad R, Calafat J (2004) Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J 23:3643–3652
Falini B, Mecucci C, Tiacci E et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–266
Falini B, Bolli N, Shan J et al (2006) Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc + AML. Blood 107:4514–4523
Bolli N, Nicoletti I, De Marco MF et al (2007) Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 67:6230–6237
Forbes DJ, Travesa A, Nord MS et al (2015) Nuclear transport factors: global regulation of mitosis. Curr Opin Cell Biol 35:78–90. doi:10.1016/j.ceb.2015.07.005
Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612
Acknowledgments
We thank Dr. Fernando Moro for helping with the analysis of binding curves and Dr. René Medema for his support. We thank the staff from the High Resolution Microscopy Facility (SGIker-UPV/EHU) for technical support. This work is funded by the Spanish Ministry of Economy (Grant SAF2014-57743-R to SB and JAR), and by the University of the Basque Country (UFI 11/20). IG-S is a recipient of a postdoctoral fellowship from the Department of Education of the Basque Country Government.
Author information
Authors and Affiliations
Corresponding authors
Additional information
A patent application on the SRV100 biosensor has been submitted by the University of the Basque Country UPV/EHU.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
García-Santisteban, I., Arregi, I., Alonso-Mariño, M. et al. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. Cell. Mol. Life Sci. 73, 4685–4699 (2016). https://doi.org/10.1007/s00018-016-2292-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-016-2292-0